Randomised, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study to Evaluate the Cardiac Safety of Two Doses of Glycopyrrolate Bromide (25 microG AND 50 microG BID) Delivered Via HFA PMDI Both Combined with Foster 100/6 microG BID Delivered Via HFA PMDI Versus Foster 100/6 microG BID Delivered Via HFA PMDI in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

Trial Profile

Randomised, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study to Evaluate the Cardiac Safety of Two Doses of Glycopyrrolate Bromide (25 microG AND 50 microG BID) Delivered Via HFA PMDI Both Combined with Foster 100/6 microG BID Delivered Via HFA PMDI Versus Foster 100/6 microG BID Delivered Via HFA PMDI in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms CARSAF
  • Most Recent Events

    • 09 Oct 2012 Planned end date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
    • 24 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Planned end date changed from 29 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top